• About
  • Advertise
  • Privacy & Policy
  • Contact
HK Businesswire
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World
    ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

    ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

    Federation secures prestigious Victorian International Education Award wins

    Federation secures prestigious Victorian International Education Award wins

    Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

    Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

    RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

    RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

    TenPay Global and Mastercard collaborate to enable fast and secure remittances to Weixin Pay

    TenPay Global and Mastercard collaborate to enable fast and secure remittances to Weixin Pay

    Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

    Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Meituan Reports Q3 2025 Results: Revenue Reaches RMB95.5 Billion as Annual Transacting Users Surpass 800 Million

    Xiaomi Founder Lei Jun Boosts Stake as Company Ramps Up Buybacks, Signaling Confidence

    Ant Group’s Multimodal AI Assistant LingGuang Surpasses 1 Million Downloads in Four Days

    Xiaomi Produces 500,000th EV in Record Time, CEO Lei Jun Pledges Focus on Safety and Delivery

    Morrison Foerster Report: ESG Committees and Climate Policy Gaining Traction Among Asia’s Largest GPs

    Xiaomi’s Double 11 GMV Surges Past RMB 29 Billion as It Claims Top Domestic Phone Sales for Third Year

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World
    ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

    ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

    Federation secures prestigious Victorian International Education Award wins

    Federation secures prestigious Victorian International Education Award wins

    Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

    Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

    RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

    RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

    TenPay Global and Mastercard collaborate to enable fast and secure remittances to Weixin Pay

    TenPay Global and Mastercard collaborate to enable fast and secure remittances to Weixin Pay

    Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

    Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Meituan Reports Q3 2025 Results: Revenue Reaches RMB95.5 Billion as Annual Transacting Users Surpass 800 Million

    Xiaomi Founder Lei Jun Boosts Stake as Company Ramps Up Buybacks, Signaling Confidence

    Ant Group’s Multimodal AI Assistant LingGuang Surpasses 1 Million Downloads in Four Days

    Xiaomi Produces 500,000th EV in Record Time, CEO Lei Jun Pledges Focus on Safety and Delivery

    Morrison Foerster Report: ESG Committees and Climate Policy Gaining Traction Among Asia’s Largest GPs

    Xiaomi’s Double 11 GMV Surges Past RMB 29 Billion as It Claims Top Domestic Phone Sales for Third Year

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
HK Businesswire
No Result
View All Result
Home News PR Newswire

UPL launches a global campaign ‘#AFarmerCan’ ahead of COP30, championing farmers in climate action

PR Newswire by PR Newswire
6 November 2025
in PR Newswire
0
UPL launches a global campaign ‘#AFarmerCan’ ahead of COP30, championing farmers in climate action
0
SHARES
12
VIEWS
Share on FacebookShare on Twitter

~ A global call to action urging world leaders to place farmers at the heart of climate strategies

Microsite: Meet 20 farmers from around the world leading climate action in agriculture
DVC: Watch the campaign video

LONDON, Nov. 7, 2025 /PRNewswire/ — UPL, a global leader in sustainable agricultural solutions, today announced the launch of its global campaign ‘#AFarmerCan – The hero you don’t know you need’, ahead of the 30th United Nations Climate Change Conference, taking place from 10-21 November 2025 in Belém, Brazil. The campaign celebrates farmers as climate heroes and calls on world leaders to recognize their pivotal role in building climate resilience.

UPL honours farmers leading climate action across the world with #AFarmerCan campaign
UPL honours farmers leading climate action across the world with #AFarmerCan campaign

With a presence in over 140 countries, UPL works closely with smallholder farmers and large-scale commercial growers, empowering them with sustainable agricultural solutions that drive climate action and food security. Drawing on this experience, UPL has curated 20 inspiring farmer stories from around the world, showcasing how agriculture can advance greenhouse gas (GHG) mitigation, energy security, water conservation, soil health regeneration, and biodiversity protection – the five pillars guiding UPL’s engagement at COP30.

UPL’s #AFarmerCan campaign makes a compelling appeal: Policy must stand with farmers. Consumers must recognize and celebrate their strength, resilience, and innovation.

As part of its campaign advocacy, UPL is proposing a four-pillar incentive framework to strengthen farmer resilience:

  • Pay: Reward farmers for adopting climate-smart practices.
  • Protect: Offer farmer subsidies and insurance to guard against risks.
  • Procure: Strengthen farmer access to public markets for certified sustainable produce.
  • Promote: Scale digital tools, soil health data, and knowledge training for farmers.

Speaking about the initiative, Mr. Jai Shroff, Chairman & Group CEO, UPL, said: “With #AFarmerCan, we are amplifying a simple but urgent message: the future of climate resilience begins in the fields. Farmers are already leading the way – innovating, adapting, and regenerating. Yet their contributions remain under-recognized in global climate discourse. This campaign is our call to policymakers, institutions, and consumers to stand with farmers, empower them, and make them central to climate action.”

UPL is amplifying its message through a global 360° campaign across Brazil and key markets, blending high-impact outdoor branding with immersive digital engagement. In Belém, the campaign spans airport signage, 1,000+ branded taxis, and 200 buses featuring QR codes that unlock powerful first-hand stories from farmers. Complementing this are targeted digital campaigns, social media activations, and an evocative film showcasing farmers as climate heroes. The initiative also includes eco-friendly merchandise — T-shirts, tote bags, and water bottles.

UPL will be present in COP30’s Blue Zone — the official area organized by the United Nations Framework Convention on Climate Change (UNFCCC) for formal negotiations and national pavilions — serving carbon-smart coffee from Brazil’s Mió brand. By serving coffee that captures more CO₂ than it emits, UPL will offer delegates a tangible experience of how climate-smart farming can accelerate progress toward global climate goals. As part of this sponsorship, UPL has also secured rights to use the conference’s official branding.

UPL will showcase its Agrosphere at the AgriZone, an exhibition space organized by Embrapa (Brazilian Agricultural Research Corporation) where UPL will host expert panels and debates based on the five pillars that guide UPL’s engagement at COP30. UPL will also participate in the Planeta Campo Forum and present a low methane rice case study from India.

Through ‘#AFarmerCan’, UPL reaffirms its commitment to shaping a global movement that celebrates farmers as climate heroes and stewards of a healthier planet.

UPL is a global leader in biosolutions and agricultural solutions, operating in over 140 countries with 43 manufacturing sites, 57 R&D facilities, and a portfolio of 15,000+ registered products worldwide.

About UPL Group

UPL Ltd. (NSE: UPL) (BSE: 512070) (LSE GDR: UPLL) is a global provider of sustainable agricultural products and solutions that cover the entire agrifood value chain. With annual revenue exceeding $5 bn, UPL Ltd. is one of the largest agriculture companies worldwide, serving growers in more than 140 countries. UPL Ltd. comprises of four pure-play platforms that include UPL Corporation Ltd. (UPL Corp); UPL Sustainable Agriculture Solutions Ltd. (UPL SAS); Advanta Enterprises Ltd; and Superform Chemistries Ltd. Together, these platforms are dedicated to Reimagining Sustainability and driving progress in the world. For more information, please visit www.upl-ltd.com.

 

Tags: prnewswire
PR Newswire

PR Newswire

PR Newswire is the industry’s leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world.

Read More

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

8 December 2025
Federation secures prestigious Victorian International Education Award wins

Federation secures prestigious Victorian International Education Award wins

8 December 2025
  • Trending
  • Comments
  • Latest
Tai Po fire death toll climbs to 44, 56 injured

Tai Po fire death toll climbs to 44, 56 injured

26 November 2025
No for now on women deacons, Vatican commission says

No for now on women deacons, Vatican commission says

4 December 2025

Ant Group’s Multimodal AI Assistant LingGuang Surpasses 1 Million Downloads in Four Days

23 November 2025
Hang Seng Indexes Company and Cyberport Partner to Drive Gen-AI Adoption in Index Calculation

Hang Seng Indexes Company and Cyberport Partner to Drive Gen-AI Adoption in Index Calculation

4 November 2025
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

8 December 2025
Federation secures prestigious Victorian International Education Award wins

Federation secures prestigious Victorian International Education Award wins

8 December 2025
Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

8 December 2025
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

8 December 2025

Recent News

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

8 December 2025
Federation secures prestigious Victorian International Education Award wins

Federation secures prestigious Victorian International Education Award wins

8 December 2025
Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

8 December 2025
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

8 December 2025
HK Businesswire

Stay ahead with the latest insights on Hong Kong’s economy, finance, and investments. From market trends to policy updates, we bring you in-depth analysis and expert opinions.

📩 Subscribe to our newsletter for exclusive updates.
📍 Follow us on social media for real-time news.
📧 Contact us: info@hongkong-invest.com

Follow Us

  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2025 by HKBusinesswire.com

No Result
View All Result

© 2025 by HKBusinesswire.com